Clinical Trial Update: The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating the safety, tolerability, and potential efficacy of IBR900 cell injections in patients with relapsed or refractory B-cell non-Ho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• IBR900 Cell Injection

Snippet

Sponsor: Imbioray (Hangzhou) Biomedicine Co., Ltd. | Conditions: Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | Phase 1 | Status: RECRUITING